https://psychedelicinvest.com/atai-life-sciences-announces-first-subject-dosed-in-phase-1-trial-of-buccal-and-iv-vls-01-a-synthetic-form-of-dmt/
Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a...
Oct 5, 2022 - Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT — atai Life Sciences N.V. (Nasdaq: ATAI),...
atai life sciencesfirst subjectin phaseand ivannounces
https://psychedelicinvest.com/atai-life-sciences-announces-key-clinical-pipeline-and-corporate-updates/
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates | Psychedelic Invest
Mar 6, 2023 - atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates — atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming...
atai life sciencesannounceskeyclinicalpipeline
https://news.dailymushroom.co/atai-life-sciences-to-present-at-the-cowen-psychedelics-novel-mechanisms-in-neuropsychiatry-summit/
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry...
atai life sciencespresentcowenpsychedelicsnovel
https://psychedelicinvest.com/atai-life-sciences-applauds-breakthrough-in-depression-treatment-with-beckley-psytechs-dmt-study/
atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study |...
Mar 27, 2024 - atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study — atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC,...
atai life sciencesdepression treatmentapplaudsbreakthroughbeckley